Keensight Capital Acquires Majority Stake in BYG4lab

BYG4lab to Acquire Finbiosoft with Support from Keensight Capital

March 14, 2024

Software

BYG4lab has signed an exclusivity agreement to acquire Finbiosoft, a Finland-based provider of quality and laboratory software for medical laboratories, with the support of Keensight Capital. The deal is intended to broaden BYG4lab's product capabilities, add Finbiosoft's technical team, and expand the group's geographic footprint across Europe and into the United States while enabling cross-selling to an expanded client base.

Keensight Capital Acquires Majority Stake in Biovian

May 23, 2018

Biotechnology

Keensight Capital has acquired a majority stake in Biovian, a Finnish contract development and manufacturing organization (CDMO) for biopharmaceuticals, alongside the company's founders, managers and Edmond de Rothschild Equity Strategies (ERES) funds. Biovian, founded in 2003 and based in Finland with ~70 employees, provides end-to-end GMP manufacturing, development and analytical services for biologics, gene therapies and vaccines; Keensight will support scaling the business to become a leading European biologics CDMO.

Keensight Capital Acquires Majority Stake in Geodesial

September 30, 2019

Software

Keensight Capital has replaced CAPZA as the majority stakeholder in Geodesial, a French developer and distributor of CAD/CAE software for infrastructure professionals. Keensight plans to support Geodesial's organic growth and execute a buy-and-build strategy to expand the company's international footprint.

Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare

May 25, 2021

Healthcare Services

Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.

Keensight Capital Acquires Majority Stake in Bedfont Scientific Ltd.

October 13, 2025

Medical Devices

Keensight Capital has acquired a majority stake in Bedfont Scientific Ltd., a UK-based designer and manufacturer of non-invasive breath analysis medical devices. The investment will support Bedfont's international expansion, product innovation and potential M&A-driven growth while existing shareholders reinvest alongside Keensight.

Keensight Capital Agrees to Acquire Quanos Solutions from IK Partners

December 20, 2022

Software

Keensight Capital has signed an agreement to acquire Quanos Solutions GmbH from IK Partners' IK Small Cap II Fund. Quanos, headquartered in Nuremberg, Germany, is a provider of industrial aftersales and digital technical documentation software (around 270 employees and 1,000+ customers); Keensight will support the company’s next phase of growth, expanding its product suite, market penetration and international reach. Financial terms were not disclosed and the deal is subject to customary approvals.